poisar

Stocks · News reference

Rezolute Raises $100 Million, Advances Ersodetug Toward Commercialization

BenzingaVandana Singh

Rezolute achieves its Phase 3 primary endpoint for ersodetug in tumor hyperinsulinism and prices a $100 million equity offering.

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Source
benzinga
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. SEC EDGARSEC EDGAR

    8-K filing — Rezolute, Inc. (RZLT)

    Filed: 2026-11-16 AccNo: 0001104659-26-127490 Size: 607 KB Item 1.01: Entry into a Material Definitive Agreement Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits